Clinical data presented at the American Diabetes Association (ADA) conference in New Orleans support's Abbott’s claim that its FreeStyle Libre 3 system is the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall mean absolute relative difference (MARD).
Minute Insight: Abbott Touts 14-Day FreeStyle Libre 3 Data
Shortly after the FDA approved Abbott's FreeStyle Libre 3 continuous glucose monitor system, the company announced new clinical data showing that it is the most accurate 14-day CGM system available.
More from Minute Insights
• By
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
• By
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
• By
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
• By
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
More from Medtech Insight
• By
Medical devices, diagnostics, and equipment face tariffs announced by President Donald Trump, despite industry pleas for exemption. The tariffs, ranging from 10%-49%, impact most countries trading with the US, potentially hindering innovation and increasing costs in the medtech sector.
• By
The US FDA has published its final document to guide sponsors on using sex-specific data in designing clinical trials of medical devices. However, the guidance removes all references to gender that appeared in January’s draft guidance, released before the Trump administration took office.